Crinetics Pharmaceuticals

Crinetics' most advanced compound is paltusotine, an oral somatostatin receptor type 2 agonist being developed for acromegaly and carcinoid syndrome. The company submitted a New Drug Application to the FDA for the acromegaly indication, which was accepted for review in early 2025. The carcinoid syndrome trial is ongoing under a Phase 3 clinical program.

Crinetics funds operations through a combination of IPO proceeds, follow-on equity offerings, and at-the-market sales programs. As of December 31, 2024, the company held $839.8 million in cash, cash equivalents and investment securities. In February 2025, Crinetics priced a follow-on stock offering expected to add roughly $500 million in gross proceeds, per its SEC filings.

The firm targets endocrine diseases and endocrine-related tumors, a relatively concentrated field within the broader rare-disease landscape. Its disclosed programs focus on acromegaly, carcinoid syndrome from neuroendocrine tumors, congenital adrenal hyperplasia and Cushing's disease.

Investment decisions rest with the company's executive leadership and Board of Directors, led by Founder, President and CEO Scott Struthers. As a publicly traded company, material capital transactions—such as the 2025 follow-on offering—are approved by the Board and disclosed in SEC filings, consistent with Nasdaq listing requirements.

As of the most recent public disclosures, Crinetics has advanced its lead program without a large-cap pharmaceutical partner, maintaining global commercial rights to paltusotine. The company has not reported any co-development or profit-sharing agreements with other biopharmaceutical firms for its lead assets, distinguishing it from the typical out-license model common in rare-disease biotech.